ORPHA:275766
Idiopathic pulmonary arterial hypertension
Also known as: IPAH · Primary pulmonary arterial hypertension
Publications
39,483
99.4th percentile
Trials
35
Interventional, condition-specific
Researchers
1,341
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
pulmonary arterial hypertension (IPAH) is a sporadic form of pulmonary arterial hypertension (PAH) characterized by elevated pulmonary arterial resistance leading to right heart failure. IPAH is and potentially fatal and not associated with an underlying condition or family history of PAH.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017147
- MONDO:0001999
- UMLS:C3203102
Additional Mondo synonyms (3)
idiopathic pulmonary arterial hypertension · primary pulmonary arterial hypertension · primary pulmonary hypertension
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
39,483 matched papers (23,896 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
35 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
39,483
39,483 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
39,483 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
23,896 in the last 10 years · medium confidence · 99.4th percentile (publications denominator)
Phrase hits: 39,483 · MeSH hits: 0
Who's working on it?
1,341
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li X9 papers · 2026
The Center for Vascular Disease and Translational Medicine, the Third Xiangya Hospital (Z.P., Yapei Li., Y.W., B.P., Z.Z., C.Q., Xiaohui Li, A.F.C.), Central South University, Changsha, China.
Papers in Europe PMC - 02Zhang Y9 papers · 2026
Division of Cardiothoracic Surgery, University of California San Diego, La Jolla, CA, USA.
Papers in Europe PMC - 03Wang Y8 papers · 2026
Department of Radiology, Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine, 510800, China.
Papers in Europe PMC - 04Li Y7 papers · 2026
Guangdong Jiangmen Chinese Medicine College, Jiangmen, PR China.
Papers in Europe PMC - 05Chen Y6 papers · 2026
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital (F.W., Z.L., W.L., H.L., H.F., S.L., C.Z., Y.Z., S.M., C.W., Z.Z., W.F., J.Z., Q.Y., M.D., W.K., A.L., J.L., X.L., X.W., N.L., Y.C., K.Y., J.W.), Guangzhou Medical University, China.
Papers in Europe PMC - 06He J6 papers · 2026
Medical Affairs Department, Gansu Provincial Hospital, Lanzhou, Gansu, China.
Papers in Europe PMC - 07Wang J (王健)6 papers · 2026
Shenzhen Key Laboratory of Microbial Genetic Engineering, Vascular Disease Research Center, College of Life Sciences and Oceanography, Guangdong Provincial Key Laboratory of Regional Immunity and Disease, Shenzhen University, China.
Papers in Europe PMC - 08Wang L6 papers · 2026
Department of Pulmonary Circulation, Shanghai Pulmonary Hospital Tongji University School of Medicine Shanghai China.
Papers in Europe PMC - 09Wang X6 papers · 2026
Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Papers in Europe PMC - 10Wu Y6 papers · 2026
The Center for Vascular Disease and Translational Medicine, the Third Xiangya Hospital (Z.P., Yapei Li., Y.W., B.P., Z.Z., C.Q., Xiaohui Li, A.F.C.), Central South University, Changsha, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
35
interventional trials for this specific condition
35 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 503 trials are registered for pulmonary arterial hypertension, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
35 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 96.1th percentile).
medium confidence · 96.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
35 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT03683186·ENROLLING BY INVITATION·A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Conditions: PAH · Pulmonary Hypertension · Pulmonary Arterial Hypertension · Hypertension·Matched via name phrase
- NCT07558460·ENROLLING BY INVITATION·Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
Conditions: Idiopathic Pulmonary Arterial Hypertension·Matched via name phrase
- NCT06104228·RECRUITING·129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Conditions: Pulmonary Arterial Hypertension · Idiopathic Pulmonary Arterial Hypertension · Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder) · Connective Tissue Diseases·Matched via name phrase
Broader category: pulmonary arterial hypertension
503
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07365332·RECRUITING·An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Conditions: Pulmonary Arterial Hypertension·Matched via name phrase
- NCT06549452·RECRUITING·Mobile Health Intervention to Improve Exercise in Pediatric PH
Conditions: Pulmonary Arterial Hypertension·Matched via name phrase
- NCT07481981·RECRUITING·A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Conditions: Pulmonary Arterial Hypertension·Matched via name phrase
- NCT06802380·NOT YET RECRUITING·Neuromodulation in Patients With Pulmonary Arterial Hypertension
Conditions: Pulmonary Hypertension·Matched via name phrase
- NCT07149935·RECRUITING·Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients
Conditions: Pulmonary Hypertension·Matched via name phrase
- NCT06176118·NOT YET RECRUITING·Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension·Matched via name phrase
- NCT06671990·NOT YET RECRUITING·The CardioMEMS Vericiguat Heart Failure Trial
Conditions: Heart Failure · Pulmonary Arterial Hypertension·Matched via name phrase
- NCT06317805·RECRUITING·Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Conditions: Pulmonary Arterial Hypertension·Matched via name phrase
- NCT06804122·RECRUITING·Exercise-based Rehabilitation in Patients With Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension·Matched via name phrase
- NCT07218029·RECRUITING·A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Conditions: Pulmonary Arterial Hypertension·Matched via name phrase
- NCT06872112·RECRUITING·A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension (PAH)·Matched via name phrase
- NCT05967299·RECRUITING·Study of Intravenous ZMA001 in Healthy Subjects
Conditions: Pulmonary Arterial Hypertension PAH·Matched via name phrase
- NCT07175038·RECRUITING·A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
Conditions: Pulmonary Arterial Hypertension (PAH) · Pulmonary Hypertension, Interstitial Lung Disease·Matched via name phrase
- NCT07697235·NOT YET RECRUITING·Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension
Conditions: PAH·Matched via name phrase
- NCT05825417·RECRUITING·Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
Conditions: Pulmonary Arterial Hypertension·Matched via name phrase
Observational and natural-history studies
12 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT01884051·RECRUITING·Hormonal, Metabolic, and Signaling Interactions in PAH
Conditions: Idiopathic Pulmonary Arterial Hypertension · Heritable Pulmonary Arterial Hypertension · Scleroderma Associated Pulmonary Arterial Hypertension · Appetite Suppressant Associate PAH·Matched via name phrase
- NCT05584722·RECRUITING·Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Conditions: Idiopathic Pulmonary Arterial Hypertension · Heritable Pulmonary Arterial Hypertension · Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo · Healthy Individuals With no Cardiopulmonary Disease·Matched via name phrase
- NCT05462574·RECRUITING·Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
Conditions: Idiopathic Pulmonary Arterial Hypertension · Heritable Pulmonary Arterial Hypertension · Pulmonary Arterial Hypertension Associated With Connective Tissue Disease·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Idiopathic pulmonary arterial hypertension" OR "Primary pulmonary arterial hypertension" OR "primary pulmonary hypertension"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Idiopathic pulmonary arterial hypertension" OR "Primary pulmonary arterial hypertension" OR "primary pulmonary hypertension"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 35 interventional · 12 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"pulmonary arterial hypertension"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: IPAH
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:38:06.270Z
